Targeting ErbB2-overexpressing cells was performed in nine patients with breast cancer at a site of metastasis in the skin, lungs, lymph nodes, liver, and chest wall and in two patients with melanoma colorectal cancers [172]. This evidence concerns the gene ERBB2 and breast carcinoma.